Ignite Creation Date:
2025-12-24 @ 2:24 PM
Ignite Modification Date:
2026-02-20 @ 4:45 PM
Study NCT ID:
NCT03630159
Status:
COMPLETED
Last Update Posted:
2022-08-15
First Post:
2018-08-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-10-09
Start Date Type:
ACTUAL
Primary Completion Date:
2021-07-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-07-20
Completion Date Type:
ACTUAL
First Submit Date:
2018-08-01
First Submit QC Date:
None
Study First Post Date:
2018-08-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-08-11
Last Update Post Date:
2022-08-15
Last Update Post Date Type:
ACTUAL